Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Grand Pharmaceutical Group Limited ( (HK:0512) ) has provided an update.
Grand Pharmaceutical Group Limited announced the successful completion of a Phase II clinical study in China for its innovative drug STC3141, aimed at treating sepsis. This breakthrough positions the company at the forefront of sepsis research, offering a novel approach by targeting immune homeostasis, potentially revolutionizing treatment options for this critical condition. The study demonstrated significant improvements in patient outcomes, confirming the drug’s efficacy and safety, and paving the way for further regulatory discussions to expedite its availability to patients.
More about Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited is a company in the pharmaceutical industry, focusing on the development of innovative drugs. Its primary products include treatments for severe and critical diseases, with a market focus on global healthcare solutions.
Average Trading Volume: 9,729,246
Technical Sentiment Signal: Buy
Current Market Cap: HK$21.05B
Learn more about 0512 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue